Related Experiment Video

Updated: May 10, 2026

Precision Implementation of Minimal Erythema Dose (MED) Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose (MED) Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

Erythema multiforme in children: the steroid debate

Melissa Chan1, Ran D Goldman

  • 1BC Children's Hospital, Department of Pediatrics, Room K4-226, Ambulatory Care Bldg, 4480 Oak St, Vancouver, BC V6H 3V4, Canada.

Canadian Family Physician Medecin De Famille Canadien
|June 15, 2013
PubMed

Insights

Erythema multiforme (EM) in children typically does not require systemic steroids for minor cases, though topical treatments may help. Systemic steroid use for severe EM major is debated, necessitating individualized treatment decisions.

Area of Science:

  • Pediatric Dermatology
  • Immunology

Background:

  • Erythema multiforme (EM) is a common skin condition in children, characterized by target lesions.
  • Clinical decisions regarding steroid treatment for EM in pediatric patients require careful consideration.

Purpose of the Study:

  • To determine when to administer steroid treatment for pediatric erythema multiforme.
  • To differentiate management strategies for EM minor versus EM major.

Main Methods:

  • Review of current recommendations and existing evidence for steroid use in pediatric EM.
  • Analysis of factors influencing treatment decisions based on disease severity.

Main Results:

  • Systemic steroids are generally not recommended for EM minor; topical steroids may offer some benefit.
  • Evidence for and against systemic steroid use in EM major is conflicting, with a lack of randomized controlled trials.

Conclusions:

  • Management of pediatric EM should be guided by disease severity.
  • Consultation with a dermatologist is advised for complex cases of EM major.
  • Further research is needed to establish definitive steroid treatment guidelines for EM.
Abstract

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Minimal Erythema Dose (MED) Testing06:24

Minimal Erythema Dose (MED) Testing

Published on: May 28, 2013

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...